GBA Presents: THE BARE ESSENTIALS
- Thread starter stonedinvestor
- Start date
--TTEC Holdings initiated with an Outperform at Barrington 08:04 TTEC
--Crown Castle price target raised to $206 from $184 at Raymond James 08:04 CCI Raymond James analyst Ric Prentiss raised the firm's price target on Crown Castle to $206 from $184 and keeps an Outperform rating on the shares following "slight beats" in Q1 earnings results and no change in FY22 adjusted FFO guidance. The analyst believes "the path to stronger tower growth is evident for the next several years" and sees U.S. carriers to become "even more active on towers as we move through 2022 and 2023."
2nd STOCK OF THE DAY- CROWN CASTLE
--Crown Castle price target raised to $206 from $184 at Raymond James 08:04 CCI Raymond James analyst Ric Prentiss raised the firm's price target on Crown Castle to $206 from $184 and keeps an Outperform rating on the shares following "slight beats" in Q1 earnings results and no change in FY22 adjusted FFO guidance. The analyst believes "the path to stronger tower growth is evident for the next several years" and sees U.S. carriers to become "even more active on towers as we move through 2022 and 2023."
2nd STOCK OF THE DAY- CROWN CASTLE
THIS COULD BE BIG>
(CATHIE HAS BEEN BUYING THIS STOCK ALMOST EVERY DAY.)
Ginkgo Bioworks announces partnership with Bayer 08:03 DNA, BAYRY<----- BIG PARTNER-!
3rd STOCK OF THE DAY- GINKO BIOWORKS
(CATHIE HAS BEEN BUYING THIS STOCK ALMOST EVERY DAY.)
Ginkgo Bioworks announces partnership with Bayer 08:03 DNA, BAYRY<----- BIG PARTNER-!
3rd STOCK OF THE DAY- GINKO BIOWORKS
watch-> Gummy Material)
Cleveland-Cliffs jumps 7% to $31.75 after Q1 results beat estimates 07:54 CLF
Cleveland-Cliffs jumps 7% to $31.75 after Q1 results beat estimates 07:54 CLF
Callaway Golf assumed with an Overweight at JPMorgan 07:18 ELY JPMorgan analyst Kevin Heenan assumed coverage of Callaway Golf (ELY) with an Overweight rating and $30 price target. The analyst sees the 2022 outlook for golf as balanced with tailwinds from pricing, channel re-stock and product innovation weighed against challenging comparisons and a broader economic reopening. He prefers shares of Callaway over Acushnet (GOLF) for the next 12 months. The year-to-date share declines present an attractive multi-year entry point to own the leading brands in an expanding and healthier golf industry, Heenan tells investors in a research note.
ELY-$23.00 <-------
ELY-$23.00 <-------
The savant gave you that earlier in the week.
As always, way ahead of the analysts.
Already up 3% on the call.
Tech is at the lowest it's been since the first rate hike btw.
If it weren't for me, all the readers and your 3 hedge funds would be broke.
UPST--- Just Keep buying!
Citi cuts Upstart target to $180 from $350, calls 'top contrarian Buy' 06:30 UPST Citi analyst Peter Christiansen lowered the firm's price target on Upstart to $180 from $350 and keeps a Buy rating on the shares. The analyst says much of the drawdown in the stock is unjustified, "mostly on business model misconceptions and/or misperceived market observations." Personal loan demand remains robust and a rising rate environment could be an "important tailwind for future debt consolidation activity," Christiansen tells investors in a research note. From here, the analyst sees the stock regaining momentum on strong Q1 results. Christiansen views Upstart as his "top contrarian Buy."
BUY BUY BUY BUY
Citi cuts Upstart target to $180 from $350, calls 'top contrarian Buy' 06:30 UPST Citi analyst Peter Christiansen lowered the firm's price target on Upstart to $180 from $350 and keeps a Buy rating on the shares. The analyst says much of the drawdown in the stock is unjustified, "mostly on business model misconceptions and/or misperceived market observations." Personal loan demand remains robust and a rising rate environment could be an "important tailwind for future debt consolidation activity," Christiansen tells investors in a research note. From here, the analyst sees the stock regaining momentum on strong Q1 results. Christiansen views Upstart as his "top contrarian Buy."
BUY BUY BUY BUY
BECAUSE IT MOVES SO SLOW I HAVE NOT REMOVED PFIZER YET. I DON'T HAVE AN OBVIOUS REPLACEMENT... This news probably won't move the stk.
WHO recommends Paxlovid COVID-19 therapy from Pfizer 06:08 PFE In a World Health Organization press release, the organization said, "WHO made a strong recommendation for nirmatrelvir and ritonavir, sold under the name Paxlovid, for mild and moderate COVID-19 patients at highest risk of hospital admission, calling it the best therapeutic choice for high-risk patients to date. However, availability, lack of price transparency in bilateral deals made by the producer, and the need for prompt and accurate testing before administering it, are turning this life-saving medicine into a major challenge for low- and middle-income countries. Pfizer's oral antiviral drug is strongly recommended for patients with non-severe COVID-19 who are at highest risk of developing severe disease and hospitalization, such as unvaccinated, older, or immunosuppressed patients. This recommendation is based on new data from two randomized controlled trials involving 3078 patients. The data show that the risk of hospitalization is reduced by 85% following this treatment. In a high-risk group, that means 84 fewer hospitalizations per 1000 patients.
WHO recommends Paxlovid COVID-19 therapy from Pfizer 06:08 PFE In a World Health Organization press release, the organization said, "WHO made a strong recommendation for nirmatrelvir and ritonavir, sold under the name Paxlovid, for mild and moderate COVID-19 patients at highest risk of hospital admission, calling it the best therapeutic choice for high-risk patients to date. However, availability, lack of price transparency in bilateral deals made by the producer, and the need for prompt and accurate testing before administering it, are turning this life-saving medicine into a major challenge for low- and middle-income countries. Pfizer's oral antiviral drug is strongly recommended for patients with non-severe COVID-19 who are at highest risk of developing severe disease and hospitalization, such as unvaccinated, older, or immunosuppressed patients. This recommendation is based on new data from two randomized controlled trials involving 3078 patients. The data show that the risk of hospitalization is reduced by 85% following this treatment. In a high-risk group, that means 84 fewer hospitalizations per 1000 patients.
Goldman Sachs expects 'positive reaction' to Snap's Q1 results 17:12 SNAP Goldman Sachs analyst Eric Sheridan keeps his Buy rating and $65 price target on Snap after its Q1 results, saying the market reaction to earnings is likely to be "positive". The stock had fallen 61% over the last six months with investor debate skewing lower in the run-up to this report, but Snap's Q1 revenue growth of 38% y/y was at the high end of its prior guidance and its DAU performance across the board was better than expected, the analyst tells investors in a research note.
I actually put ELY on a watch list earlier this week.
I like that stock. They are hosting an investor day next week.
I suspect an announcement.
